Johnson & Johnson Ends Development of Investigational Therapy Imaavy in Rheumatoid Arthritis Due to Study Failure
ByAinvest
Friday, Aug 29, 2025 12:18 pm ET1min read
JNJ--
Imaavy, a potential key driver of top-line growth, was being studied in combination with anti-TNFα therapy. The mid-stage trial, which included difficult-to-treat patients with rheumatoid arthritis, did not show a significant improvement in outcomes when compared to the anti-TNFα therapy alone. Rheumatoid arthritis is an autoimmune disease that causes pain, swelling, and stiffness in the joints [1].
Despite the setback, Imaavy remains under evaluation for several other indications, including chronic inflammatory demyelinating polyneuropathy (CIDP), hemolytic anemia due to high-dose intravenous immunoglobulin (HDFN), wAIHA (warm autoimmune hemolytic anemia), and Sjogren's disease. The company is continuing to conduct late-stage studies for these conditions, which could potentially open up new revenue streams [1].
The discontinuation of Imaavy for rheumatoid arthritis is a strategic move by J&J, focusing its resources on more promising areas. The company's commitment to immunology and neuroscience indications underscores its long-term growth strategy. The peak sales for Imaavy, if successful in other indications, are expected to reach $5 billion [1].
References:
[1] https://www.reuters.com/business/healthcare-pharmaceuticals/jj-drops-development-combination-arthritis-drug-after-trial-setback-2025-08-28/
Johnson & Johnson has discontinued the development of Imaavy in rheumatoid arthritis due to phase IIa study failure. The combination therapy with anti-TNFα did not show sufficient evidence of a significant added benefit. Imaavy remains a potential key driver of top-line growth, with peak sales expected to reach $5 billion. J&J is evaluating the drug in several immunology and neuroscience indications, including late-stage studies for CIDP, HDFN, wAIHA, and Sjogren's disease.
Johnson & Johnson (JNJ.N) has announced that it will discontinue the development of its combination drug, Imaavy, in patients with rheumatoid arthritis. The decision follows the failure of a phase IIa trial to demonstrate sufficient evidence of a significant added benefit over existing anti-tumor necrosis factor alpha (anti-TNFα) therapy [1].Imaavy, a potential key driver of top-line growth, was being studied in combination with anti-TNFα therapy. The mid-stage trial, which included difficult-to-treat patients with rheumatoid arthritis, did not show a significant improvement in outcomes when compared to the anti-TNFα therapy alone. Rheumatoid arthritis is an autoimmune disease that causes pain, swelling, and stiffness in the joints [1].
Despite the setback, Imaavy remains under evaluation for several other indications, including chronic inflammatory demyelinating polyneuropathy (CIDP), hemolytic anemia due to high-dose intravenous immunoglobulin (HDFN), wAIHA (warm autoimmune hemolytic anemia), and Sjogren's disease. The company is continuing to conduct late-stage studies for these conditions, which could potentially open up new revenue streams [1].
The discontinuation of Imaavy for rheumatoid arthritis is a strategic move by J&J, focusing its resources on more promising areas. The company's commitment to immunology and neuroscience indications underscores its long-term growth strategy. The peak sales for Imaavy, if successful in other indications, are expected to reach $5 billion [1].
References:
[1] https://www.reuters.com/business/healthcare-pharmaceuticals/jj-drops-development-combination-arthritis-drug-after-trial-setback-2025-08-28/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet